

Tecentriq reasserts its breast cancer position



[Jacob Plieth](#)

If Tecentriq's breakthrough in first-line triple-negative breast cancer ultimately ended up somewhat muted, Roche now has a chance to reassert its authority. This is courtesy of the neoadjuvant Impassion-031 study, which today read out positively for pathological complete response. Tecentriq plus Abraxane is approved for first-line TNBC, but only in patients expressing PD-L1 at 1% or greater, as a result of the Impassion-130 trial, whose marginal all-comers benefit disappointed ([Tecentriq gets its narrow breast cancer label, March 11, 2019](#)). However, Impassion-030, in which Tecentriq plus Abraxane-containing chemo was given before surgery, has shown a benefit versus chemo alone regardless of PD-L1 expression, Roche says. The full data, including the extent to which PD-L1 expressers drive the overall benefit, have yet to be scrutinised, but Impassion-031 might allow Roche to establish Tecentriq as a standard in an all-comers setting, ie before that of Impassion-131, which would accordingly become less important. This could also neutralise the threat of Merck & Co's Keytruda, whose TNBC successes comprise [the front-line Keynote-355 trial, albeit in \$\geq 10\%\$ PD-L1 expressers](#), and [Keynote-522, a neoadjuvant/adjuvant study](#). And Tecentriq's failure in another neoadjuvant trial, NeoTRIPaPDL1, now becomes easier to dismiss.

Roche trials in triple-negative breast cancer

Study	Design	Primary endpoint(s)	Result
<i>Neoadjuvant</i>			
Impassion-031	Tecentriq + Abraxane vs Abraxane	pCR in PD-L1+ and all-comers	Toplined positive in PD-L1+ and all-comers
<i>Neoadjuvant + adjuvant</i>			
NeoTRIPaPDL1	Tecentriq + Abraxane vs Abraxane	EFS	Failed in Dec 2019
MO39875	Tecentriq + chemo vs chemo	pCR & EFS	Dec 2023 primary completion
<i>Adjuvant</i>			
Impassion-030	Tecentriq + chemo vs chemo	iDFS	Jan 2022 primary completion
<i>First-line</i>			
Impassion-130	Tecentriq + Abraxane vs Abraxane	OS & PFS in PD-L1+ and all-comers	Approved in $\geq 1\%$ PD-L1
Impassion-131	Tecentriq + paclitaxel vs paclitaxel	PFS in PD-L1+ and all-comers	Upsized by 11%, completion delayed from Feb to Nov 2019; still no data
Impassion-132	Tecentriq + chemo vs chemo	OS in PD-L1+ and all-comers	Upsized by 63%, completion delayed from Jul 2019 to Jan 2023
Ipatunity-130	Ipatasertib + chemo vs chemo	PFS in PIK3CA/AKT1/PTEN-altered	Dec 2021 primary completion

Source: clinicaltrials.gov & company presentation.

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:+14082073770800)

Evaluate Americas
[+1-617-573-9450](tel:+16175739450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+8108011644754)

© Copyright 2022 Evaluate Ltd.